期刊文献+

塞来昔布/希罗达节拍化疗治疗老年晚期胃癌的临床研究 被引量:3

The Clinical Study of Celecoxib Combined with Xeloda Metronomic Chemotherapy in the Treatment of the Elderly with Advanced Gastric Cancer
原文传递
导出
摘要 目的:评价塞来昔布(Celecoxib)联合希罗达(Xeloda)节拍化疗(metronomic chemotherapy)治疗老年晚期胃癌的客观疗效及毒副反应,探讨老年晚期胃癌高缓解率、低毒性的治疗方法。方法:45例患者随机分为两组。治疗组23例,采用塞来昔布与希罗达节拍化疗,Celecoxib 200 mg Bid,Xeloda 500 mg Bid,连续服药,直至病情进展。4周为一周期,至少1周期后评定疗效。对照组22例,采用FOLFOX4方案化疗:L-OHP 85 mg/m2 iv gtt 2 h d1,CF 200mg/m2 iv gtt 2 h d1、d2,5-FU400 mg/m2 iv bolus d1、d2,5-FU600 mg/m2 civ 22 h d1、d2。每2周重复,4周为1周期,至少1周期后评定疗效。结果:45例患者均获得随访。治疗组与对照组总有效率(RR)、疾病控制率(DCR)、生活质量改善率(QOL)分别为47.8%(11/23)、50.0%(11/22);91.3%(21/23)、63.6%(14/22);82.6%(19/23)、54.5%(12/22)。两组患者中位疾病进展时间(mTTP)、中位生存期(MST)分别为9.5个月、5.5个月;13.5个月、9个月。治疗组与对照组1年生存率分别为56.5%(13/23)、27.3%(6/22)。两组总有效率差异无统计学意义(P>0.05),生活质量改善率、疾病控制率、1年生存率差异有统计学意义(P<0.05)。治疗组毒副反应轻微。结论:塞来昔布联合希罗达节拍化疗治疗老年晚期胃癌安全、有效,患者得到生存受益,依从性好,效价比高,值得临床进一步研究。 Objective:To evaluate the efficacy and side-effects of Celecoxib combined with Xeloda metronomic chemotherapy in the treatment of the elderly with advanced gastric cancer.Methods:45 cases of elderly advanced gastric cancer were divided into two groups randomly.The observed group(23 cases)was treated with Celecoxib and Xeloda metronomic chemotherapy(Celecoxib 200 mg P.O B.i.d and Xeloda 500 mg P.O B.i.d,continuously until progression of disease),and the contrast group(22 cases) with FOLFOX4 regimen(L-OHP 85mg/m2 ivgtt 2 h d1,CF 200 mg/m2 ivgtt 2 h followed by 5-FU 400 mg/m2 iv bolus and 5-FU 600 mg/m2 civ 22 h d1,d2,repeated every 2 weeks).The efficacy and the side-effects were evaluated.Results:The total effective rates /disease control rates /improvement of QOL of the observed group and contrast group were 47.8%(11/23)and 50.0%(11/22);91.3%(21/23)and 63.6%(14/22);82.6%(19/23)and 54.5%(12 /22),respectively.The mTTP of two groups were 9.5 months and 5.5 months,MST were 13.5 months and 9months,respectively.The survival rates for 1 year of the observed group and contrast group were 56.5%(13/23)、27.3%(6/22),respectively.There was no significant difference in the total effective rates(P〉0.05),but differences were statistically significant in QOL,DCR and the survival rates for 1 year(P〈0.05).The toxicity of the observed group is mild.Conclusion:Celecoxib combined with Xeloda metronomic chemotherapy is effective and safe for the elderly with advanced gastric cancer.The paitents can gain survival benefit from this treatment.Further clinical study shoud be warranted.
出处 《华西医学》 CAS 2009年第8期2027-2030,共4页 West China Medical Journal
关键词 晚期胃癌 节拍化疗 塞来昔布 希罗达 老年人 advanced gastric cancer metronomic chemotherapy celecoxib xeloda the elderly
  • 相关文献

参考文献12

二级参考文献37

共引文献458

同被引文献32

  • 1Kerbel RS, Klement G, Pritchard KL, et a. 1 Continuous lowdose anti - angiogenie./metronomic chemotherapy: from the research laboratory into the oncology clinic[J]. Ann Onco,2002,13(1) : 12 -15.
  • 2Gately S, Kerbel R. Antiangiogenie scheduling of lower dose cancer chemotherapy[J]. Cancer J ,2001,7(5) :427 -436.
  • 3Scharovsky OG, Mainetti LE, Rozados VR. Metronomic chemotherapy: changing the paradigm thatmore is better [ J ]. Current Ontology, 2009, 16(2) : 7 - 15.
  • 4Mancuso P, Colleoni M, Calleri A, et al. Circulating endothelialcellkinetics and viability predictsurvival in breastcancerpatients receivingmetronomic chemotherapy[ J ]. Blood, 2006, 108 (2) :452 - 459.
  • 5Kamat AA, Kim TJ. Landen CN, et el. Metronomic chemotherapy Enhances the efficacy of antivascuhar therapy in ovarian cancer [ J ]. Cancer Res,2007,67( 1 ) :281 -288.
  • 6Regazzoni S, Pesce G, Marini G, et al. Low - dose continuous intravenous infusion of 5 -fluorouracil for metastatic breast cancer [ J]. Ann 0nco,1996, 7:807-813.
  • 7Coneale P, Cerretani D, Remondo C, et al. A novelmetronomic chemotherapy regimen ofweekly platinum and daily oral etoposide in high - risk non - small cell lung cancer patients [J].Oncol Rep, 2006, 164:133-140:.
  • 8Bottini A, Generali D, Brizzi MP, et al. Randomized phase II trial of letrozole and letrozole plus low - dosemetronomic oral cyclophosphamide asprimary systemic treatment in elderly breastcancer patients [J]. J Clin Onco,2006, 24(22) : 3623 -3628.
  • 9Franchi F, Grassi P, Ferro D, ctal. Antiangiogenicmetronomic chemotherapy and hyperthermia in the palliation of advanced cancer [J]. Eur J Cancer Care (Engl), 2007, 16 (3) : 258 -262.
  • 10孙燕,石远凯.临床肿瘤内科手册[M].北京:人民卫生社出版.2007.152.

引证文献3

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部